Experimental comparison of the in vivo efficacy of two novel anticancer therapies

Vera S. Ruzanova, Anastasia S. Proskurina, Genrikh S. Ritter, Yaroslav R. Efremov, Valeriy P. Nikolin, Nelly A. Popova, Vasiliy A. Naprimerov, Evgenia V. Dolgova, Ekaterina A. Potter, Svetlana S. Kirikovich, Evgeniy V. Levites, Zakhar S. Mustafin, Sergey A. Lashin, Ekaterina A. Burakova, Dmitry A. Stetsenko, Alexandr A. Ostanin, Elena R. Chernykh, Sergey S. Bogachev

Research output: Contribution to journalArticlepeer-review


Background/Aim: We compared the therapeutic efficacy of two recently developed experimental anticancer technologies: 1) in situ vaccination based on local immunotherapy with CpG oligonucleotides and anti-OX40 antibodies to activate antitumor immune response and 2) "Karanahan" technology [from the Sanskrit kāraa ('source') + han ('to kill')] based on the combined injection of cyclophosphamide and double-stranded DNA to eradicate cancer stem cells. Materials and Methods: The anticancer approaches were compared on three types of mouse malignant tumors with different grades of immunogenicity: weakly immunogenic carcinoma Krebs-2, moderately immunogenic Lewis carcinoma, and highly immunogenic A20 B-cellular lymphoma. Results: Our results indicated that in situ vaccination was the most effective against the highly immunogenic tumor A20. In addition, "Karanahan" demonstrated high efficiency in all types of tumors, regardless of their immunogenicity or size. Conclusion: "Karanahan" therapy showed higher efficacy relative to in situ vaccination with CpG oligonucleotides and anti-OX40 antibodies.

Original languageEnglish
Pages (from-to)3371-3387
Number of pages17
JournalAnticancer research
Issue number7
Publication statusPublished - Jul 2021


  • Anti-OX40 antibody
  • CpG oligonucleotides
  • Cyclophosphamide
  • Double-stranded DNA
  • Karanahan technology
  • Antigens, Neoplasm/immunology
  • Immunotherapy/methods
  • Male
  • Oligodeoxyribonucleotides/immunology
  • Cyclophosphamide/immunology
  • Antibodies/immunology
  • DNA/immunology
  • Lymphoma/immunology
  • Mice, Inbred CBA
  • Female
  • Carcinoma, Lewis Lung/immunology
  • Receptors, OX40/immunology
  • Mice, Inbred C57BL
  • Antigens, Differentiation/immunology
  • Antineoplastic Agents/immunology
  • Vaccination/methods
  • Neoplastic Stem Cells/immunology
  • Animals
  • Cell Line, Tumor
  • Mice
  • Mice, Inbred BALB C




Dive into the research topics of 'Experimental comparison of the in vivo efficacy of two novel anticancer therapies'. Together they form a unique fingerprint.

Cite this